A Study of LY3305677 in Participants With Obesity Or Overweight
ClinicalTrials.gov · NCT05623839 · Registry updated: 2023-07-05
- Condition / research focus
- Overweight; Obesity
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2022-11-16. Completion: 2023-06-27 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- LY3305677 (drug)
- Placebo (drug)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Anaheim Clinical Trials, LLC
Anaheim, California, United States
Site recruitment: Not reported - ICON Early Phase Services
San Antonio, Texas, United States
Site recruitment: Not reported - ICON Early Phase Services Lenexa Center
Salt Lake City, Utah, United States
Site recruitment: Not reported